Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070640 · ClinicalTrials.gov registry record · NA
Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy
A NA study of Cholecystitis, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT02070640: Completed NA study of Cholecystitis, sponsored by Ohio State University.
NCT02070640 is a NA study of Cholecystitis that has completed, run by Ohio State University. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02070640, a NA study of Cholecystitis, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate an imaging system using Indocyanine Green (ICG) to assist in real-time identification of anatomy during cholecystectomy (gallbladder removal). We propose to define the effectiveness of NIRF-C in identifying the cystic duct junction during cholecystectomy.
Primary Outcome
A patient's negative reaction to indocyanine green (ICG) will be monitored from the time of injection through the 2 week post-operative follow-up visit.
Conditions Studied
Interventions
- DRUG Injection of indocyanine green (ICG)
- DEVICE Near Infrared Cholangiography Fluorescence (NIRF-C)
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-08 |
| Phase | NA |
What the finished NCT02070640 record still lists
NCT02070640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Cholecystitis appearing as the primary indexed condition, and to 2 interventions - of which Injection of indocyanine green (ICG) is the first listed.
NCT02070640 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02070640 about?
NCT02070640 is a clinical study titled "Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy". The purpose of this study is to evaluate an imaging system using Indocyanine Green (ICG) to assist in real-time identification of anatomy during cholecystectomy (gallbladder removal). We propose to define the effectiveness of NIRF-C in identifying the cystic duct junction during cholecystectomy.
What is the current status of trial NCT02070640?
This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2013-01. Estimated completion is 2014-08.
What conditions does trial NCT02070640 study?
This clinical trial studies the following conditions: Cholecystitis.
What interventions are being tested in trial NCT02070640?
The interventions under investigation include: Injection of indocyanine green (ICG) (DRUG), Near Infrared Cholangiography Fluorescence (NIRF-C) (DEVICE).
Who is sponsoring clinical trial NCT02070640?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02070640 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholecystitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02070640's enrollment target sits among peer trials
99 920th of 2000 higher than 1,079 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia